11 Followers on Owler
InflaRx is a Germany-based biopharmaceutical company that develops and commercializes monoclonal antibodies for the treatment of inflammatory diseases...
Read moreInflaRx is a Germany-based biopharmaceutical company that develops and commercializes monoclonal antibodies for the treatment of inflammatory diseases...
Read more
News
Mar 22, 2023
BioSpace
InflaRx: InflaRx Reports Full Year 2022 Financial and Operating Results
Jan 06, 2023
Marketscreener
InflaRx: InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
Dec 22, 2022
Yicai Global
InflaRx: Germany's InflaRx, China's Staidson Surge After Agreeing on Covid-19 Drug Sales
Dec 21, 2022
ChinaBio Today
InflaRx: Staidson Bio In-Licenses mAb Complement Therapy for COVID in $10 Million Deal
Dec 21, 2022
BioSpace
InflaRx: InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
Nov 09, 2022
FirstWord Pharma
InflaRx: InflaRx Reports Third Quarter 2022 Financial & Operating Results
Nov 09, 2022
StreetInsider
Press Release: InflaRx : InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
Oct 03, 2022
PMLiVE
InflaRx: InflaRx seeks FDA authorisation for vilobelimab for critically ill COVID-19 patients
Sep 09, 2022
Benzinga
InflaRx: InflaRx to Present at Upcoming Scientific and Investor Conferences
Aug 05, 2022
Benzinga
InflaRx: InflaRx: Q2 Earnings Insights
Looking for similar companies to InflaRx?
InflaRx News
InflaRx Press Releases
InflaRx Headquarters
InflaRx Summary
ABOUT
Overview
InflaRx is a Germany-based biopharmaceutical company that develops and commercializes monoclonal antibodies for the treatment of inflammatory diseases. InflaRx was founded in 2007. InflaRx's headquarters is located in Jena, Thuringia, DE 07745. Infla...CEO
InflaRx's Co-Founder & CEO, Niels C. Riedemann, currently has an approval rating of 88%. InflaRx's primary competitors are Akari Therapeutics, ChemoCentryx, Alnylam and 18 more.Website
inflarx.comCompetitors
View 21 InflaRx competitors here.Acquisitions
There have been no acquisitions found related to InflaRxInvestments
Recent investment data cannot be found related to InflaRxFrequently Asked Questions about InflaRx
When was InflaRx founded?
InflaRx was founded in 2007Who is InflaRx's CEO?
InflaRx's CEO is Niels C. RiedemannHow much revenue does InflaRx generate?
InflaRx generates $ < 1M in revenueHow much funding does InflaRx have?
InflaRx has historically raised $218.9M in funding
Where is InflaRx's headquarters?
InflaRx's headquarters is in Jena Thuringia, DEHow many employees does InflaRx have?
InflaRx has 49 employeesWhat sector does InflaRx operate in?
InflaRx is in Biotechnology, PharmaceuticalsWho are InflaRx's competitors?
InflaRx's top competitors are Akari Therapeutics, ChemoCentryx, Alnylam